AJTMH Tropical Medicine and Hygiene News
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 60(6), 1999, pp. 1045-1050
Copyright © 1999 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lang, J
Right arrow Articles by Blondeau, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lang, J
Right arrow Articles by Blondeau, C
Related Collections
Right arrow Yellow Fever
Right arrow Vaccine
American Journal of Tropical Medicine and Hygiene, Vol 60, Issue 6, 1045-1050
Copyright © 1999 by American Society of Tropical Medicine and Hygiene

Research Articles


Comparison of the immunogenicity and safety of two 17D yellow fever vaccines

J Lang, J Zuckerman, P Clarke, P Barrett, C Kirkpatrick, and C Blondeau

As part of the clinical validation process of a new working seed of a licensed yellow fever vaccine (new working seed PV26, Stamaril; Pasteur Merieux Connaught, Lyon, France), the immunogenicity and safety of two batches of this vaccine (PM-YF) were compared with those of another commercially available vaccine (Arilvax; Evans Medical-Wellcome, Liverpool, United Kingdom) in 211 healthy adults. While the geometric mean titer values at days 10-14 and day 28 after vaccination were higher in the PM-YF group, the vaccines provided equivalent seroprotection (titers > or = 1/10) one month after a single vaccine dose (100% PM-YF versus 99% W-YF; P = 0.001, by one-sided equivalence test). Both vaccines were safe. There were no serious local or systemic reactions reported, nor any clinically significant hepatic function abnormalities associated with the use of either vaccine. These two 17D yellow fever vaccines from different European vaccine manufacturers were highly immunogenic and safe, and provided equivalent seroprotection.


This article has been cited by other articles:


Home page
 CVIHome page
M. Niedrig, O. Kursteiner, C. Herzog, and K. Sonnenberg
Evaluation of an Indirect Immunofluorescence Assay for Detection of Immunoglobulin M (IgM) and IgG Antibodies against Yellow Fever Virus
Clin. Vaccine Immunol., February 1, 2008; 15(2): 177 - 181.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
M. PFISTER, O. KURSTEINER, H. HILFIKER, D. FAVRE, P. DURRER, A. ENNAJI, J. L'AGE-STEHR, A. KAUFHOLD, and C. HERZOG
IMMUNOGENICITY AND SAFETY OF BERNA-YF COMPARED WITH TWO OTHER 17D YELLOW FEVER VACCINES IN A PHASE 3 CLINICAL TRIAL
Am J Trop Med Hyg, March 1, 2005; 72(3): 339 - 346.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Society of Tropical Medicine and Hygiene.